BeOne Medicines (BEIGF) Work In Process (2024 - 2026)

BeOne Medicines (BEIGF) has 3 years of Work In Process data on file, last reported at $109.2 million in Q1 2026.

• Work In Process for Q1 2026 came in at $109.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $109.2 million (changed N/A YoY), and the FY2025 annual result was $122.7 million, up 104.07% from the prior year.
• Work In Process slipped to $109.2 million in Q1 2026 per BEIGF's latest filing, from $122.7 million in the prior quarter.
• Over five years, Work In Process peaked at $122.7 million in Q4 2025 and troughed at $60.1 million in Q4 2024.
• A 3-year average of $97.3 million and a median of $109.2 million in 2026 frame the typical range for Work In Process.
• On a YoY basis, Work In Process climbed as much as 104.07% in 2025 and fell as far as 104.07% in 2025.
• A 3-year view of Work In Process shows it stood at $60.1 million in 2024, then soared by 104.07% to $122.7 million in 2025, then fell by 10.98% to $109.2 million in 2026.
• Business Quant data shows BEIGF's Work In Process at $109.2 million in Q1 2026, $122.7 million in Q4 2025, and $60.1 million in Q4 2024.